RAF265
RAF265 is a potent and orally active RAF/VEGFR2 inhibitor.
Product Specifications
CAS Number
[927880-90-8]
Product Name Alternative
CHIR-265
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; Autophagy; Raf; VEGFR
Type
Reference compound
Related Pathways
Apoptosis; Autophagy; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/RAF265.html
Purity
99.80
Solubility
DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C) |Ethanol : 10 mg/mL (ultrasonic)
Smiles
FC(F)(C1=CN=C(N1)C2=NC=CC(OC3=CC=C4N(C(NC5=CC=C(C(F)(F)F)C=C5)=NC4=C3)C)=C2)F
Molecular Formula
C24H16F6N6O
Molecular Weight
518.41
Precautions
H302, H315, H319, H335
References & Citations
[1]Mordant P, et al. Dependence on phosphoinositide 3-kinase and RAS-RAF pathways drive the activity of RAF265, a novel RAF/VEGFR2 inhibitor, and RAD001 (Everolimus) in combination. Mol Cancer Ther. 2010 Feb;9 (2) :358-68.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
Raf; VEGFR2/KDR/Flk-1
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MR218616L4V 200 µL
Gemin5 (NM_001166671) Mouse Tagged ORF Clone Lentiviral Particle
Ask
View Details 
GTR15277959 1 Vial
Lentiviral mouse Hoxc9 shRNA (UAS) - Lentiviral mouse Hoxc9 shRNA (UAS, iRFP) (100)
Ask
View Details